Alzheimer's disease (AD) is a progressive and complex neurodegenerative disease in which the γ-secretase-mediated amyloid-β (Aβ) pathology plays an important role. We found that a multifunctional protein, β-arrestin1, facilitated the formation of NCT/APH-1 (anterior pharynx-defective phenotype 1) precomplex and mature γ-secretase complex through its functional interaction with APH-1. Deficiency of β-arrestin1 or inhibition of binding of β-arrestin1 with APH-1 by small peptides reduced Aβ production without affecting Notch processing. Genetic ablation of β-arrestin1 diminished Aβ pathology and behavioral deficits in transgenic AD mice. Moreover, in brains of sporadic AD patients and transgenic AD mice, the expression of β-arrestin1 was upreg...
BACKGROUND: We describe molecular processes that can facilitate pathogenesis of Alzheimer's disease ...
The γ-secretase complex processes numerous Type I membrane proteins by cleavage within their TM doma...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
β-arrestins are associated with numerous aspects of G protein-coupled receptor (GPCR) signaling and ...
Increase in the generation and deposition of amyloid-β (Aβ) plays a central role in the development ...
γ-Secretases are a family of intramembrane cleaving aspartyl proteases and important drug targets in...
AbstractThe γ-secretase complex comprises presenilin (PS), nicastrin (NCT), anterior pharynx-defecti...
A central question in Alzheimer's disease (AD) research is what role β-amyloid peptide (Aβ) plays in...
As γ-secretase is the final protease involved in the production of Aβ peptides, which accumulate in ...
As γ-secretase is the final protease involved in the production of Aβ peptides, which accumulate in ...
Proteolytic processing of amyloid precursor protein (APP) plays a critical role in pathogenesis of A...
Autosomal dominant mutations in the genes for amyloid precursor protein (APP) and the presenilins (p...
SummaryDevelopment of disease-modifying therapeutics is urgently needed for treating Alzheimer disea...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
Gamma-secretase is the protease responsible for amyloid beta peptide release and is needed for Notch...
BACKGROUND: We describe molecular processes that can facilitate pathogenesis of Alzheimer's disease ...
The γ-secretase complex processes numerous Type I membrane proteins by cleavage within their TM doma...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
β-arrestins are associated with numerous aspects of G protein-coupled receptor (GPCR) signaling and ...
Increase in the generation and deposition of amyloid-β (Aβ) plays a central role in the development ...
γ-Secretases are a family of intramembrane cleaving aspartyl proteases and important drug targets in...
AbstractThe γ-secretase complex comprises presenilin (PS), nicastrin (NCT), anterior pharynx-defecti...
A central question in Alzheimer's disease (AD) research is what role β-amyloid peptide (Aβ) plays in...
As γ-secretase is the final protease involved in the production of Aβ peptides, which accumulate in ...
As γ-secretase is the final protease involved in the production of Aβ peptides, which accumulate in ...
Proteolytic processing of amyloid precursor protein (APP) plays a critical role in pathogenesis of A...
Autosomal dominant mutations in the genes for amyloid precursor protein (APP) and the presenilins (p...
SummaryDevelopment of disease-modifying therapeutics is urgently needed for treating Alzheimer disea...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...
Gamma-secretase is the protease responsible for amyloid beta peptide release and is needed for Notch...
BACKGROUND: We describe molecular processes that can facilitate pathogenesis of Alzheimer's disease ...
The γ-secretase complex processes numerous Type I membrane proteins by cleavage within their TM doma...
Development of disease-modifying therapeutics is urgently needed for treating Alzheimer disease (AD)...